Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia

Authors

  • A Ghasemi
  • B Keikhaei
  • R Ghodsi
Abstract:

Background Sickle hemoglobin is the most common abnormal hemoglobin in the United States. Hemoglobin S arises as a result of a single amino acid substitution (glutamic acid to valin at position 6 of the β-globine chain). The presence of fetal hemoglobin (HbF) plays a relatively protective role since a significant amount of HbF interferes with HbS polymerization, the pathogenesis mechanism of the vaso-occlusive symptoms that are the major contributor of the morbidity and mortality of this condition Thalassemia major and thalassemia intermedia have no specific molecular correlate but encompass a wide spectrum of clinical and laboratory abnormalities. Hydroxyurea (HU), an s-phase-specific and non-DNA-hypomethylating chemotherapeutic agents is capable of inducing HbF synthesis. Materials and Methods This study was done on 56 patients, 28 patients with sickle cell anemia (SCA) and 28 patients with intermediate or major β-thalassemia. Start dose of HU was 10 mg/kg per day and increased by 5 mg/kg per day every 4-6 weeks until toxicity or according to clinical response. Results The side effects were dermatologic in 39.28%, neurologic 23.2%, gastrointestinal 17.5% and hematologic 10.71% of patients. the statistical analysis didn't show significant relationship between variables such as history of blood transfusion, duration of HU treatment, age of start HU, age of diagnosis, dose of HU and ethnic with occurrence of HU adverse effects. Conclusion The HU therapy in our patients tolerated well and side effects were minor to moderate, benign and transient.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

side effects of hydroxyurea in patients with thalassemia major and thalassemia intermedia and sickle cell anemia

background sickle hemoglobin is the most common abnormal hemoglobin in the united states. hemoglobin s arises as a result of a single amino acid substitution (glutamic acid to valin at position 6 of the β-globine chain). the presence of fetal hemoglobin (hbf) plays a relatively protective role since a significant amount of hbf interferes with hbs polymerization, the pathogenesis mechanism of th...

full text

Side Effects of Hydroxyurea in Patients with Sickle Cell Anemia

Background: Hemoglobin S arises is the result of a point mutation (A-T) in the sixth codon on the -globin gene on chromosome 11 causing sickle cell anemia. The presence of fetal hemoglobin in infancy plays a relatively protective role for vaso-occlusive symptoms that are the major contributor for the morbidity and mortality among patients with sickle cell anemia. hydroxyurea, an s-phase-specif...

full text

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum level...

full text

side effects of hydroxyurea in patients with sickle cell anemia

background: hemoglobin s arises is the result of a point mutation (a-t) in the sixth codon on the -globin gene on chromosome 11 causing sickle cell anemia. the presence of fetal hemoglobin in infancy plays a relatively protective role for vaso-occlusive symptoms that are the major contributor for the morbidity and mortality among patients with sickle cell anemia. hydroxyurea, an s-phase-specif...

full text

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum level...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 3

pages  114- 117

publication date 2014-09

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023